GlassScriptPhysician profile
Ralph J Cifaldi
NPI 1508965344
$2,805.99
in general payments reported to CMS, 2019-2025
29 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $298 · 2021: $558 · 2022: $425 · 2023: $435 · 2024: $305 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.66 |
| Education | $183.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $714.23 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $597.99 | 2019-2025 | Veozah |
| Abbvie INC. | $225.23 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $169.54 | 2019-2025 | Capvaxive, Gardasil 9 |
| Pfizer INC. | $154.28 | 2021-2025 | |
| Glaxosmithkline, LLC. | $118.10 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $102.14 | 2019-2024 | Lokelma, Airsupra |
| Myovant Sciences INC. | $89.78 | 2022 | |
| Exact Sciences Corporation | $56.90 | 2023-2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $56.71 | 2020-2021 | |
| Allergan, INC. | $48.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.71 | 2019-2023 | Jardiance |
| Amarin Pharma, INC. | $44.10 | 2020-2021 | |
| Lilly USA, LLC | $40.28 | 2021-2025 | Jardiance |
| Arbor Pharmaceuticals, INC. | $39.55 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $32.14 | 2022 | |
| Indivior INC. | $31.66 | 2025 | Sublocade |
| Amgen INC. | $29.10 | 2021-2025 | Repatha |
| Almatica Pharma LLC | $28.93 | 2022 | |
| Exeltis, USA INC. | $28.17 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $27.30 | 2021 | |
| Lupin INC. | $26.98 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.82 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $14.74 | 2022 | |
| Sanofi Pasteur INC. | $14.52 | 2023 | |
| Xeris Pharmaceuticals, INC. | $13.75 | 2023 | Gvoke Hypopen |
| Evofem Biosciences, INC. | $13.63 | 2022 | |
| Shire North American Group INC | $12.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Cifaldi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.